EIK1001 + pembrolizumab + paclitaxel + carboplatin

A combination regimen comprised of **EIK1001**, **pembrolizumab**, **paclitaxel**, and **carboplatin**, investigated primarily as an antineoplastic therapy in oncology clinical trials. - **Pembrolizumab** is a monoclonal antibody checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1), enhancing T-cell-mediated immune responses against tumors. - **Paclitaxel** is a microtubule-stabilizing chemotherapeutic agent that disrupts mitosis, leading to apoptosis in rapidly dividing cancer cells. - **Carboplatin** is a platinum-containing chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and leading to cell death. - **EIK1001** is a candidate drug whose specific mechanism and developer are currently unconfirmed in public databases. The combination is under investigation for solid tumors, leveraging immunotherapy with established chemotherapeutic backbones.